Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-29T18:49:08.709Z Has data issue: false hasContentIssue false
  • English
  • Français

Iloprost in persistent pulmonary hypertension of the newborn

Published online by Cambridge University Press:  24 May 2005

Michael Ehlen  and
Beatrix Wiebe
Michael Ehlen
Affiliation:
Department of Neonatology and Pediatric Intensive Care, Kinderklinik St. Augustin, St. Augustin, Germany
Beatrix Wiebe
Affiliation:
Department of Neonatology and Pediatric Intensive Care, Kinderklinik St. Augustin, St. Augustin, Germany
Get access Rights & Permissions [Opens in a new window]

Abstract

Aerosolized iloprost is now used as a therapeutic option in the treatment of pulmonary hypertension. We report on the administration of this derivative of prostacycline in treating severe pulmonary hypertension of the newborn. The combination of iloprost instilled endotracheally and inhaled was chosen as a last attempt at treatment in a critically ill patient who did not respond to advanced conventional treatments, including high frequency oscillation and inhalation of nitric oxide. The use of iloprost converted permanently the right-to-left shunting, leading to a substantial improvement in oxygenation.

Keywords

Prostacyclineinhaled therapyright-to-left shunting
Type
Brief Report
Information
Cardiology in the Young , Volume 13 , Issue 4 , August 2003 , pp. 361 - 363
Copyright
© 2003 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ehlen M, Esser R, Kipping T. Inhalative Anwendung von Iloprost bei pulmonaler Hypertonie und respiratorischer Insuffizienz im Kindesalter. Monatsschr Kinderheilkd 2003; 151: 539–543.Google Scholar
Möller JC. Iloprost inhalation in early therapy of pediatric lung failure. Journal für Anästhesie und Intensivbehandlung 2000; 7: 150.Google Scholar
Köster S, Ahrens P, Kohl M, Wygold T. Verhindert frühzeitig inhalativ verabreichtes Iloprost beim Krankheitsbild der persistierenden pulmonalen Hypertonie (PPHN) die Intubationshäufigkeit? Anwendungsbeobachtung bei 6 Patienten. Kinderärztliche Praxis 2002; 6: 18, V48.Google Scholar
Olschewski H, Simonneau G, Galie N, et al. Inhaled Iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329.Google Scholar
Römer U, Kozlik-Feldmann R, Behr J. Inhalatives Iloprost zur Therapie der schweren pulmonalen Hypertension: Erste Erfahrungen im Kindesalter. Zeitschrift für Kardiologie 2001; 90: 680.Google Scholar
Lambert V, Serraf A, Durand P, Losay J. Aerosolized iloprost therapy in an infant with chronic pulmonary hypertension after a neonatal arterial switch operation. Arch Pediatr 2001; 8: 1218–1221.Google Scholar
Max M, Rossaint R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur J Pediatr 1999; 158 (Suppl I): I23–I26.Google Scholar
Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of newborn. Pediatr Cardiol 1997; 18: 3–7.Google Scholar
Olschewski H, Grimminger F, Seeger W. Therapie der pulmonalen Hypertonie. In: Schäfers HJ, Seeger W (eds). Pulmonale Hypertonie, Blackwell Wiss.-Verl, 2000, pp 83–106.
De Jaegere AP, van den Anker JN. Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. Eur Resp J 1998; 12: 932–934.Google Scholar